[First experiences with BS 100-141, a new antihypertensive substance].
The administration of a new guanidine derivate, BS 100-141, to 20 patients resulted in a statistically highly significant reduction of blood pressure. A comparative clinical trial of BS 100-141 and alpha-methyl-DOPA showed BS 100-141 to be more efficient in lowering the arterial pressure than alpha-methyl-DOPA, especially when the drug was used in the second period of treatment. In the majority of the patients treated with BS 100-141 a slight increase in blood glucose concentration, not exceeding the upper limits of normal values, was found.
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010648:Phenylacetates / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D001786:Blood Glucose; D006146:Guanidines; D010648:Phenylacetates; D008750:Methyldopa
Erste Erfahrungen mit BS 100-141, einer neuen blutdrucksenkenden Substanz